Stock Analysis, Dividends, Split History

SBGI / Sinclair Broadcast Group, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,150.91
Enterprise Value ($M)4,964.50
Book Value ($M)1,621.17
Book Value / Share21.16
Price / Book1.33
NCAV ($M)-3,317.37
NCAV / Share-43.30
Price / NCAV-0.65
Share Statistics
Common Shares Outstanding2 76,079,830
Common Shares Outstanding 25,670,684
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.11
Return on Assets (ROA)0.10
Return on Equity (ROE)1.01
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio2.96
Income Statement (mra) ($M)
Other Non Media Revenue69,279,000.00
Media Revenue2,543,876,000.00
Advertising Barter Transactions Advertising Barter Revenue120,963,000.00
Operating Income737.51
Net Income594.10
Earnings Per Share Basic5.77
Earnings Per Share Diluted5.72
Cash Flow Statement (mra) ($M)
Cash From Operations431.10
Cash from Investing-198.03
Cash from Financing-198.03
Identifiers and Descriptors
Central Index Key (CIK)912752
Related CUSIPS
829226959 829226901 829226110 829226909 082922610

Split History

Stock splits are used by Sinclair Broadcast Group, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Deals of the day-Mergers and acquisitions

2018-09-06 reuters
Sept 6 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Thursday: (23-0)

Exclusive: Tribune Media in new sale talks after Sinclair deal collapse - sources

2018-09-05 reuters
(Reuters) - U.S. TV station owner Tribune Media Co (TRCO.N) is kicking off a new round of talks to sell itself after its planned $3.9 billion sale to peer Sinclair Broadcast Group Inc (SBGI.O) failed to get regulatory clearance, people familiar with the matter said on Wednesday. (3-0)

7 Stocks Set for Monster Growth in 2018

2018-08-30 investorplace
Although stocks have experienced a rough start so far in 2018, some stocks still have a big chance to shine this year. The best stocks to buy now go above and beyond the normal growth prospects. While looking for these kinds of investments, I examined seven of the best stocks to invest in, all with huge upside potential and support from the Street’s top analysts. (21-2)

Deals of the day-Mergers and acquisitions

2018-08-30 reuters
Aug 30 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Thursday: (3-0)

Sinclair files countersuit against Tribune

2018-08-29 reuters
(Reuters) - Sinclair Broadcast Group Inc (SBGI.O) said on Wednesday it has filed a counterclaim in a Delaware court to Tribune Media Co’s (TRCO.N) lawsuit filed in early August against the company claiming a breach of contract. (2-0)

CUSIP: 829226109